PMID- 36066461
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20230426
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 128
IP  - 21
DP  - 2022 Nov 1
TI  - Image analysis reveals differences in tumor multinucleations in Black and White 
      patients with human papillomavirus-associated oropharyngeal squamous cell 
      carcinoma.
PG  - 3831-3842
LID - 10.1002/cncr.34446 [doi]
AB  - BACKGROUND: Understanding biological differences between different racial groups 
      of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma 
      (OPSCC) patients, who have differences in terms of incidence, survival, and tumor 
      morphology, can facilitate accurate prognostic biomarkers, which can help develop 
      personalized treatment strategies. METHODS: This study evaluated whether there 
      were morphologic differences between HPV-associated tumors from Black and White 
      patients in terms of multinucleation index (MuNI), an image analysis-derived 
      metric that measures density of multinucleated tumor cells within epithelial 
      regions on hematoxylin-eosin images and previously has been prognostic in 
      HPV-associated OPSCC patients. In this study, the authors specifically evaluated 
      whether the same MuNI cutoff that was prognostic of overall survival (OS) and 
      disease-free survival in their previous study, T(TR) , is valid for Black and 
      White patients, separately. We also evaluated population-specific cutoffs, T(B) 
      for Blacks and T(W) for Whites, for risk stratification. RESULTS: MuNI was 
      statistically significantly different between Black (mean, 3.88e-4; median, 
      3.67e-04) and White patients (mean, 3.36e-04; median, 2.99e-04), with p = .0078. 
      Using T(TR) , MuNI was prognostic of OS in the entire population with hazard 
      ratio (HR) of 1.71 (p = .002; 95% confidence interval [CI], 1.21-2.43) and in 
      White patients with HR of 1.72 (p = .005; 95% CI, 1.18-2.51). Population-specific 
      cutoff, T(W) , yielded improved HR of 1.77 (p = .003; 95% CI, 1.21-2.58) for 
      White patients, whereas T(B) did not improve risk-stratification in Black 
      patients with HR of 0.6 (p = .3; HR, 0.6; 95% CI, 0.2-1.80). CONCLUSIONS: 
      Histological difference between White and Black patient tumors in terms of 
      multinucleated tumor cells suggests the need for considering population-specific 
      prognostic biomarkers for personalized risk stratification strategies for 
      HPV-associated OPSCC patients.
CI  - (c) 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of 
      American Cancer Society.
FAU - Koyuncu, Can F
AU  - Koyuncu CF
AUID- ORCID: 0000-0001-5990-2226
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
AD  - Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
FAU - Nag, Reetoja
AU  - Nag R
AUID- ORCID: 0000-0001-8707-3840
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
FAU - Lu, Cheng
AU  - Lu C
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
FAU - Corredor, German
AU  - Corredor G
AUID- ORCID: 0000-0003-3002-0937
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
AD  - Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
FAU - Viswanathan, Vidya S
AU  - Viswanathan VS
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
FAU - Sandulache, Vlad C
AU  - Sandulache VC
AD  - Baylor College of Medicine, Houston, Texas, USA.
AD  - Otolaryngology-Head and Neck Surgery, Operative Care Line, Michael E. DeBakey 
      Veterans Affairs Medical Center, Houston, Texas, USA.
FAU - Fu, Pingfu
AU  - Fu P
AD  - Department of Population and Quantitative Health Sciences, Case Western Reserve 
      University, Cleveland, Ohio, USA.
FAU - Yang, Kailin
AU  - Yang K
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Pan, Quintin
AU  - Pan Q
AD  - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, 
      Ohio, USA.
FAU - Zhang, Zelin
AU  - Zhang Z
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
FAU - Xu, Jun
AU  - Xu J
AD  - Nanjing University of Information Science and Technology, Nanjing, China.
FAU - Chute, Deborah J
AU  - Chute DJ
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Thorstad, Wade L
AU  - Thorstad WL
AD  - Washington University in St. Louis, St. Louis, Missouri, USA.
FAU - Faraji, Farhoud
AU  - Faraji F
AUID- ORCID: 0000-0001-5078-813X
AD  - University of California San Diego, San Diego, California, USA.
FAU - Bishop, Justin A
AU  - Bishop JA
AD  - University of Texas Southwestern Medical Center, Dallas, Texas, USA.
FAU - Mehrad, Mitra
AU  - Mehrad M
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Castro, Patricia D
AU  - Castro PD
AD  - Baylor College of Medicine, Houston, Texas, USA.
FAU - Sikora, Andrew G
AU  - Sikora AG
AD  - Baylor College of Medicine, Houston, Texas, USA.
FAU - Thompson, Lester D R
AU  - Thompson LDR
AD  - Southern California Permanente Medical Group, Pasadena, California, USA.
FAU - Chernock, Rebecca D
AU  - Chernock RD
AD  - Washington University in St. Louis, St. Louis, Missouri, USA.
FAU - Lang Kuhs, Krystle A
AU  - Lang Kuhs KA
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Wasman, Jay K
AU  - Wasman JK
AD  - School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Luo, Jingqin R
AU  - Luo JR
AD  - Washington University in St. Louis, St. Louis, Missouri, USA.
FAU - Adelstein, David J
AU  - Adelstein DJ
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Koyfman, Shlomo A
AU  - Koyfman SA
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Lewis, James S Jr
AU  - Lewis JS Jr
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Madabhushi, Anant
AU  - Madabhushi A
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, Georgia, USA.
AD  - Atlanta Veterans Administration Medical Center, Atlanta, Georgia, USA.
AD  - Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
LA  - eng
GR  - CX001953/VA/VA/United States
GR  - C06 RR012463/RR/NCRR NIH HHS/United States
GR  - U24 CA199374/CA/NCI NIH HHS/United States
GR  - U01 CA239055/CA/NCI NIH HHS/United States
GR  - R01 HL158071/HL/NHLBI NIH HHS/United States
GR  - IK2 CX001953/CX/CSRD VA/United States
GR  - R01 CA268287/CA/NCI NIH HHS/United States
GR  - R01 CA249992/CA/NCI NIH HHS/United States
GR  - R01 HL151277/HL/NHLBI NIH HHS/United States
GR  - R01 CA220581/CA/NCI NIH HHS/United States
GR  - R01 CA216579/CA/NCI NIH HHS/United States
GR  - R01 CA268207/CA/NCI NIH HHS/United States
GR  - R01 CA202752/CA/NCI NIH HHS/United States
GR  - R01 CA208236/CA/NCI NIH HHS/United States
GR  - U01 CA248226/CA/NCI NIH HHS/United States
GR  - I01 BX004121/BX/BLRD VA/United States
GR  - R43 EB028736/EB/NIBIB NIH HHS/United States
GR  - P30 CA091842/CA/NCI NIH HHS/United States
GR  - U01 CA269181/CA/NCI NIH HHS/United States
GR  - K07 CA218247/CA/NCI NIH HHS/United States
GR  - T32 DC000028/DC/NIDCD NIH HHS/United States
GR  - R01 CA257612/CA/NCI NIH HHS/United States
GR  - U54 CA254566/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220906
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers)
RN  - TDQ283MPCW (Eosine Yellowish-(YS))
RN  - YKM8PY2Z55 (Hematoxylin)
SB  - IM
MH  - *Alphapapillomavirus
MH  - Biomarkers
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Eosine Yellowish-(YS)
MH  - *Head and Neck Neoplasms/complications
MH  - Hematoxylin
MH  - Humans
MH  - *Oropharyngeal Neoplasms
MH  - Papillomaviridae
MH  - *Papillomavirus Infections
MH  - Prognosis
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/complications
PMC - PMC9782693
MID - NIHMS1837107
OTO - NOTNLM
OT  - Black
OT  - HPV
OT  - MuNI
OT  - OPSCC
OT  - White
OT  - image analysis
COIS- Rebecca D. Chernock reports funding from Caris Life Sciences and Merck. Deborah 
      J. Chute reports book royalties. German Corredor reports a grant from the US 
      Department of Defense. Farhoud Faraji reports funding from the National Institute 
      on Deafness and Other Communication Disorders and Stand Up To Cancer. James S. 
      Lewis Jr reports a grant from National Institutes of Health and payment as an 
      expert witness from Shook, Hardy, and Bacon. Jingqin R. Luo reports a grant from 
      National Institutes of Health. Anant Madabhushi reports grants from AstraZeneca, 
      Boehringer Ingelheim, and Bristol-Myers Squibb; consulting fees from Aiforia, 
      Caris, and SimBioSys; participation as a fiduciary officer with Picture Health; 
      and stock options with Elucid Bioimaging. Andrew G. Sikora reports consulting 
      fees from F. Hoffmann-La Roche. Lester D.R. Thompson reports funding from 
      Elsevier. Jun Xu reports a grant from the National Natural Science Foundation of 
      China. Kailin Yang reports grants from the Conquer Cancer Foundation, the 
      National Cancer Institute, and RSNA Research and Education Foundation; and travel 
      funding from Case Comprehensive Cancer Center and Case Western Reserve 
      University. The other authors made no disclosures.
EDAT- 2022/09/07 06:00
MHDA- 2022/10/18 06:00
PMCR- 2023/01/08
CRDT- 2022/09/06 10:33
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/03/21 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/09/06 10:33 [entrez]
PHST- 2023/01/08 00:00 [pmc-release]
AID - CNCR34446 [pii]
AID - 10.1002/cncr.34446 [doi]
PST - ppublish
SO  - Cancer. 2022 Nov 1;128(21):3831-3842. doi: 10.1002/cncr.34446. Epub 2022 Sep 6.